WST
West Pharmaceutical ServicesPrevious close
412.62
Change
−4.05 / −0.97%
P/E (TTM) ?
53.4
Market Cap
$27.6B
1M
+11.29%
S&P 500 −0.91% over same period
Volume / Avg Volume
1.1M / 772K
1.38× average
Latest earnings analysisFY2026 Q2Reported 2026-07-23
West Pharmaceutical Q2 2026: revenue up 13.8%, guidance raised
West beat its own guidance and consensus and raised the full-year outlook, so the quarter's numbers are strong. Revenue of $872.3 million rose 13.8% and adjusted EPS of $2.37 rose 28.8%, with full-year adjusted EPS guidance lifted to $8.85–$9.05. The blemish: West Vantage grew 0.8% organically and its margins fell. The rest of this note explains where the money came from and what to watch.
Read the full analysis →Revenue$0.87BYoY +13.80%
EPS (non-GAAP)$2.37Beatest. $2.10
Next-quarter revenue guidance$0.83B ±0.9%YoY −5.10%
Next-day move−7.67%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-07-23 | $872M | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-04-23 | $845M | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-02-12 | $3.1B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-10-23 | $805M | Pending |
| FY2025 Q2 Quarter ended 2025-06 | 2025-07-24 | $767M | Pending |
| FY2025 Q1 Quarter ended 2025-03 | 2025-04-24 | $698M | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 93 of its 5-year rangeExpensive
5-year range 32.9 – 54.7 · Median 43.5
Last 4 quarters: $685M in buybacks + $62.8M in dividends, 2.71% of market cap combined
P/E (TTM)
53.4
P/B
10.1
P/S
9.1
Dividend Yield
0.33%
Earnings Reaction
Over the last 6 reports, the stock moved ±3.7% on average on the first trading day after, rising 2 times
Most recent −7.67%
Guidance Credibility
Of the last 2 next-quarter revenue guides, 2 were met; actual results averaged 6.1% above guidance
Volatility & Correlation
1-year beta 0.61 · Correlation with S&P 500 0.25Low beta
Annualized volatility 31% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 4 · $5.4MNet selling $5.4M
- 09-15Favorite Annette FSr. VP & Chief HR OfficerSell$0.92M2,524 shares · Avg price 365.00
- 09-14Favorite Annette FSr. VP & Chief HR OfficerSell$0.89M2,500 shares · Avg price 355.00
- 09-11Favorite Annette FSr. VP & Chief HR OfficerSell$0.86M2,500 shares · Avg price 345.00
- 09-08Favorite Annette FSr. VP & Chief HR OfficerSell$2.8M8,135 shares · 3 trades · Avg price 340.81
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q3 | 0.87 | +8.7% | 39.7% | 0.21 | 3.02 |
| FY2026 Q2 | 0.87 | +13.8% | 37.7% | 0.15 | 2.15 |
| FY2026 Q1 | 0.84 | +21.0% | 35.1% | 0.14 | 1.92 |
| FY2025 Q4 | 0.81 | +7.5% | 37.8% | 0.13 | 1.82 |
| FY2025 Q3 | 0.80 | +7.7% | 36.6% | 0.14 | 1.92 |
| FY2025 Q2 | 0.77 | +9.2% | 35.7% | 0.13 | 1.82 |
| FY2025 Q1 | 0.70 | +0.4% | 33.2% | 0.09 | 1.23 |
| FY2024 Q4 | 0.75 | +2.3% | 36.5% | 0.13 | 1.78 |
| FY2024 Q3 | 0.75 | −0.1% | 35.4% | 0.14 | 1.85 |
| FY2024 Q2 | 0.70 | −6.9% | 32.8% | 0.11 | 1.51 |
| FY2024 Q1 | 0.70 | −3.0% | 33.1% | 0.12 | 1.55 |
| FY2023 Q4 | 0.73 | +3.3% | 38.0% | 0.14 | 1.83 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| WST | 53.4 | +8.7% | 39.7% | +11.29% | Bullish |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |